Every material Form 8-K Sarepta Therapeutics filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sarepta Therapeutics agreed to exchange about $291.4 million of its 1.25% Convertible Senior Notes due 2027 for an equal principal amount of new 4.875% Convertible Senior Notes due 2030, plus about $31.6 million in cash. The new notes were issued on December 18, 2025, and bring the total outstanding 2030 notes to about $893.4 million, which affects the company's debt structure and the terms shareholders hold.
Exchange covers about $291.4 million of 2027 notes, paid with an equal principal amount of 2030 notes plus about $31.6 million in cash
New 4.875% Convertible Senior Notes due 2030 were issued December 18, 2025, under the August 28, 2025 indenture
Total 4.875% notes due 2030 outstanding after the exchange: about $893.4 million, up from about $602.0 million issued in August 2025
Exchange Agreements were entered December 10, 2025, including a trust affiliated with director Michael Chambers
Sarepta reported third-quarter 2025 total revenues of $399.4 million, down 15% from $467.2 million a year earlier, and a GAAP net loss of $179.9 million, or $1.80 per diluted share, compared with GAAP net income of $33.6 million a year earlier. The filing also disclosed that the ESSENCE confirmatory trial for AMONDYS 45 and VYONDYS 53 did not reach statistical significance on its primary endpoint, and the company plans to meet with the FDA about a path to traditional approval.
Total revenues were $399.4 million versus $467.2 million a year earlier; ELEVIDYS net product revenue fell $49.5 million after shipments to non-ambulatory patients in the U.S. were suspended in June 2025.
GAAP diluted loss per share was $1.80, compared with earnings of $0.34; non-GAAP diluted loss per share was $0.13, compared with earnings of $0.64.
A $138.6 million loss on debt extinguishment and $40.5 million in restructuring charges were recorded in the quarter.
Cash, cash equivalents, restricted cash and investments were $865.2 million at September 30, 2025, down from $1,503.5 million at December 31, 2024.
Sarepta Therapeutics exchanged $700.0 million of its 1.25% convertible notes due 2027 for $602.0 million of new 4.875% convertible notes due 2030, 5,851,693 shares of common stock and about $123.3 million in cash. The new notes were issued August 28, 2025, and the company also sold 1,106,806 shares to J. Wood Capital Advisors LLC at $18.07 per share, so shareholders face a new debt obligation alongside potential dilution from share issuance and conversion.
Exchanged $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due September 1, 2030, plus 5,851,693 shares and about $123.3 million in cash
New notes have an initial conversion price of about $60.00 per share, versus $20.58 last reported sale price on August 20, 2025
Interest is payable March 1 and September 1 each year, beginning March 1, 2026
Concurrent private placement of 1,106,806 shares to J. Wood Capital Advisors LLC at $18.07 per share
Sarepta Therapeutics said Bilal Arif, its Executive Vice President and Chief Technical Operations Officer until August 12, 2025, will leave the company as part of a strategic restructuring and pipeline prioritization. He will serve as a consultant through December 31, 2025, and the filing gives a $576,700 severance payment and a $400 hourly consulting fee.
Employment ends effective September 16, 2025; Arif serves as Special Advisor to the President until then
Separation and Consulting Agreement dated August 12, 2025, with consulting through December 31, 2025
Severance lump sum of $576,700 and consulting fee of $400 per hour
Outstanding equity awards as of August 12, 2025 continue to vest during his employment or consulting period
Sarepta said it will cut about 36% of its workforce, roughly 500 employees, as part of a restructuring that pauses most limb-girdle muscular dystrophy gene therapy programs and focuses on siRNA candidates. It also reported preliminary second-quarter 2025 net product revenue of $513 million and said the FDA has requested a black box warning for ELEVIDYS, while several executives were reassigned or named to new roles. The filing gives no prior-period revenue comparison, and the one-time charge and label change may weigh on shareholders.
Board approved a reduction in force of about 36% of workforce on July 14, 2025, with a one-time third-quarter 2025 charge estimated at $32 million to $37 million, nearly all cash
Preliminary Q2 2025 total net product revenue was $513 million, including $282 million from ELEVIDYS and $231 million from RNA-based PMOs; final results are due in early August 2025
FDA requested a black box warning for acute liver injury and acute liver failure in the ELEVIDYS label, which Sarepta agreed to
Ian Estepan named President and Chief Operating Officer and Ryan Wong named Chief Financial Officer, both effective July 16, 2025; Dallan Murray, Chief Customer Officer, is departing
At its annual meeting on June 5, 2025, Sarepta Therapeutics stockholders approved an increase of 4,300,000 shares to the 2018 Equity Incentive Plan, bringing the total to 17,487,596 shares, and a 300,000-share increase to the employee stock purchase plan, bringing it to 1,700,000 shares. Stockholders also re-elected four Class II directors, approved executive pay on an advisory basis, and ratified KPMG LLP as auditor for 2025. The larger share reserves govern how many shares can be issued under those plans.
Stockholders approved a 4,300,000-share increase to the 2018 Equity Incentive Plan, to 17,487,596 shares in total.
Stockholders approved a 300,000-share increase to the employee stock purchase plan, to 1,700,000 shares in total.
Richard J. Barry received 64,757,685 For votes and 9,565,547 Against; Stephen L. Mayo, Ph.D. received 73,289,653 For votes and 1,051,656 Against.
On the advisory pay vote, 72,144,292 shares were For and 2,176,998 Against; KPMG LLP was ratified with 80,588,115 For and 3,875,497 Against.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sarepta Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →